 |
|
|
| |
NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan
|
| |
| |
Several new HCV drugs including HCV protease inibitors, polymerase inhibitors, and nitazoxanide will be highlights at this EASL meeting. These drugs are the most advanced in development and are being studied in HCV+ patients. So, development for these drugs are on a fast track. Although telaprevir is the furthest along in development with phase III starting, and boceprevir is expected to start phase III, my observation is that several other drugs are close behind so a regimen with 2 or more oral drugs is possible within a few years. Jules Levin
Sunday, Symposium 9: CLINICAL: NEW DEVELOPMENTS IN HCV THERAPY
Chairperson: Maria Buti-Ferret, Spain
10:30 TARGETS FOR HCV THERAPY
J-M. Pawlotsky
France
10:50 CLINICAL RESULTS OF PROTEASE AND POLYMERASE INHIBITORS
S. Zeuzem
Germany
11:10 ANTIVIRAL RESISTANCE TYPES OF DRUG RESISTANCE AND MANAGEMENT
M. Sulkowski
USA
11:30 PERSPECTIVES IN INTERFERON AND IMMUNE THERAPIES
H. Wedemeyer
Germany
11:40 DISCUSSION
NEW DRUGS
(these are the titles of the presentations at EASL; full reports will follow from NATAP after the data is presented).
EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NÁVE CHRONIC HCV PATIENTS
BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS
HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN
TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY
SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY
POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS
POTENT ANTIVIRAL ACTIVITY OF SECOND GENERATION NUCLEOSIDE INHIBITORS, IDX102 AND IDX184, IN HCV-INFECTED CHIMPANZEES
RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4
PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NÁVE SUBJECTS WITH HEPATITIS C
LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO
STUDIES OF THE POTENTIAL FOR RESISTANCE TO NITAZOXANIDE OR TIZOXANIDE
IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION
A NEW CLASS OF POTENT INHIBITORS OF HCV RNA-DEPENDANT RNA POLYMERASE
ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER
PRECLINICAL PHARMACOKINETIC AND ADME CHARACTERIZATION OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV NS5B POLYMERASE INHIBITOR
RESULTS OF A SAFETY, TOLERABILITY AND PHARMACOKINETIC PHASE I STUDY OF VCH-916, A NOVEL POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS
|
| |
|
|
|
|
|
